SGLT2 inhibitors, such as dapagliflozin and empagliflozin, were particularly effective in reducing the risk of heart failure and improving renal outcomes, as evidenced in the DAPA-HF [15] and EXSCEL [14] analyses, where reductions in worsening heart failure, cardiovascular death, and eGFR decline were significant. The gene discussed is SLC5A2; the disease is heart failure.